Vision Sensing Acquisition said it filed a late 10-Q for the period ended March 31, less than a week after it received a Nasdaq warning about the tardy report.
Vision Sensing in January announced a deal with Mediforum, a biomedical company developing treatments for Alzheimer’s and memory enhancement. Established in 2015, Mediforum is headquartered in Seoul, South Korea.
The merger consideration is $250 million in stock.
If the deal is approved, the combined company intends to list on the Nasdaq. Read more.
